For Immediate Release
Chicago, IL – April 12, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Alphabet Inc.
GOOGL
, Amazon.com, Inc.
AMZN
, AbbVie Inc.
ABBV
, Walmart Inc.
WMT
and Toyota Motor Corp.
TM
.
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for Alphabet, Amazon and AbbVie
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Alphabet Inc., Amazon.com, Inc., and AbbVie Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>>
Shares of
Alphabet
have outperformed the Zacks Internet – Services industry over the past year (+18.8% vs. +2.8%) on the back of the search giant’s leverage to ad spending and strong cloud division. Alphabet’s expanding data centers will continue to bolster its presence in the cloud space. Further, major updates in its search segment are enhancing the search results.
The Zacks analyst believes that Google’s mobile search is gaining solid momentum. Also, a strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. Further, its deepening focus on the wearables category remains a tailwind.
The company’s growing efforts to gain a foothold in the healthcare industry are other positives. Also, Alphabet’s expanding presence in the autonomous driving space is contributing well. However, its growing litigation issues and increasing expenses are concerns.
(You can
read the full research report on Alphabet here >>>
)
Amazon
shares have gained lagged the broader market over the past year (-10.4% vs +9%) on persistent worries that the company’s Covid outperformance was at the expense of future results. There is also the issue of growth stocks in the Fed tightening cycle. These are reasonable issues, but the Zacks analyst sees the company well positioned for the long run given solid Prime momentum and solid positioning in the cloud space (Amazon Web Services or AWS). Further, robust Alexa skills and expanding smart home products portfolio are positives.
The Zacks analyst believes that a strong global presence and solid momentum among the small and medium businesses remain tailwinds. However, growing expenses associated with supply-chain constraints and labor supply shortages remain concerns.
(You can
read the full research report on Amazon here >>>
)
Shares of
AbbVie
have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+69.1% vs. +38.7%). The Zacks analyst believes that Humira has been performing well in the United States based on strong demand trends. AbbVie has several new drugs in its portfolio, which can drive revenues once Humira loses U.S. exclusivity in 2023. Skyrizi and Rinvoq are going strong. It has an impressive late-stage pipeline with several early/mid-stage candidates that have blockbuster potential.
Allergan’s acquisition has diversified AbbVie’s revenue base into new therapeutic area. However, there are concerns about long-term sales growth once Humira generics enter the U.S. market. Increasing competition from newer therapies is hurting Imbruvica’s sales.
(You can
read the full research report on Abbvie here >>>
)
Other noteworthy reports we are featuring today include Walmart Inc. and Toyota Motor Corp..
Why Haven’t You Looked at Zacks’ Top Stocks?
Our 5 best-performing strategies have blown away the S&P’s impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%,
and
+95.3%
. Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report